Assessment Of Duration Of Action, Safety & Toleration Of UK369,003 and Cialis In Patients With Erectile Dysfunction
Phase 2
Completed
- Conditions
- Impotence
- Registration Number
- NCT00174486
- Lead Sponsor
- Pfizer
- Brief Summary
Assessment of duration of action, safety \& toleration of different formulations and doses of UK-369,003 and Cialis in patients with male erectile dysfunction. Patients should have previously been on PDE5 inhibitors and have been respondents to the drug. Duration of treatment is 4 weeks.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 300
Inclusion Criteria
- Erectile Dysfunction
Exclusion Criteria
- Alpha blockers and Nitrates of any preparation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Assessment of duration of action, safety & toleration of the investigational drug and Cialis
- Secondary Outcome Measures
Name Time Method Assess safety & toleration over 4 week treatment period